Literature DB >> 19383825

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Junko Suzuki1, Yunn-Yi Chen, Gary K Scott, Sandy Devries, Koei Chin, Christopher C Benz, Frederic M Waldman, E Shelley Hwang.   

Abstract

PURPOSE: Excess histone deacetylase (HDAC) activity can induce hypoacetylation of histone and nonhistone protein substrates, altering gene expression patterns and cell behavior potentially associated with malignant transformation. However, HDAC expression and protein acetylation have not been studied in the context of breast cancer progression. EXPERIMENTAL
DESIGN: We assessed expression levels of acetylated histone H4 (ac-H4), ac-H4K12, ac-tubulin, HDAC1, HDAC2, and HDAC6 in 22 reduction mammoplasties and in 58 specimens with synchronous normal epithelium, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) components. Differences among groups were tested for significance using nonparametric tests.
RESULTS: From normal epithelium to DCIS, there was a marked reduction in histone acetylation (P < 0.0001). Most cases showed similar levels of acetylation in DCIS and IDC, although some showed further reduction of ac-H4 and ac-H4K12 from DCIS to IDC. Expression of HDAC1, HDAC2, and HDAC6 was also significantly reduced but by a smaller magnitude. Greater reductions of H4 acetylation and HDAC1 levels were observed from normal to DCIS in estrogen receptor-negative compared with estrogen receptor-positive, and in high-grade compared with non-high-grade tumors.
CONCLUSION: Overall, there was a global pattern of hypoacetylation associated with progression from normal to DCIS to IDC. These findings suggest that the reversal of this hypoacetylation in DCIS and IDC could be an early measure of HDAC inhibitor activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383825      PMCID: PMC3746548          DOI: 10.1158/1078-0432.CCR-08-2319

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry.

Authors:  Liwen Zhang; Xiaodan Su; Shujun Liu; Amy R Knapp; Mark R Parthun; Guido Marcucci; Michael A Freitas
Journal:  J Proteome Res       Date:  2007-01       Impact factor: 4.466

Review 2.  HDAC6 a new cellular stress surveillance factor.

Authors:  Patrick Matthias; Minoru Yoshida; Saadi Khochbin
Journal:  Cell Cycle       Date:  2007-10-15       Impact factor: 4.534

3.  Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.

Authors:  Qun Zhou; Peter Atadja; Nancy E Davidson
Journal:  Cancer Biol Ther       Date:  2007-01       Impact factor: 4.742

4.  Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

Authors:  Mahmoud A Mohamed; Philipp A Greif; James Diamond; Osama Sharaf; Perry Maxwell; Rodolfo Montironi; Robert A M Young; Peter W Hamilton
Journal:  BJU Int       Date:  2007-04       Impact factor: 5.588

Review 5.  Clinical development of histone deacetylase inhibitors as anticancer agents.

Authors:  Daryl C Drummond; Charles O Noble; Dmitri B Kirpotin; Zexiong Guo; Gary K Scott; Christopher C Benz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

6.  Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.

Authors:  Katsuyoshi Ishihama; Mitsunori Yamakawa; Shuho Semba; Hiroaki Takeda; Sumio Kawata; Seishi Kimura; Wataru Kimura
Journal:  J Clin Pathol       Date:  2007-08-24       Impact factor: 3.411

7.  Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma.

Authors:  Xueli Bai; Lihua Wu; Tingbo Liang; Zhiqiang Liu; Junjian Li; Donglin Li; Haiyang Xie; Shengyong Yin; Jun Yu; Qi Lin; Shusen Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-05       Impact factor: 4.553

8.  Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

Authors:  Pamela Münster; Douglas Marchion; Elona Bicaku; Morgen Schmitt; Ji Hyun Lee; Ronald DeConti; George Simon; Mayer Fishman; Susan Minton; Chris Garrett; Alberto Chiappori; Richard Lush; Daniel Sullivan; Adil Daud
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  Global histone modifications predict prognosis of resected non small-cell lung cancer.

Authors:  Fabrice Barlési; Giuseppe Giaccone; Marielle I Gallegos-Ruiz; Anderson Loundou; Simone W Span; Pierre Lefesvre; Frank A E Kruyt; Jose Antonio Rodriguez
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

Review 10.  HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Authors:  C Boyault; K Sadoul; M Pabion; S Khochbin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

View more
  46 in total

1.  Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.

Authors:  Aditya Sudheer Vaidya; Bhargava Karumudi; Emma Mendonca; Antonett Madriaga; Hazem Abdelkarim; Richard B van Breemen; Pavel A Petukhov
Journal:  Bioorg Med Chem Lett       Date:  2012-06-18       Impact factor: 2.823

2.  Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.

Authors:  Lauren L Atwell; Zhenzhen Zhang; Motomi Mori; Paige Farris; John T Vetto; Arpana M Naik; Karen Y Oh; Philippe Thuillier; Emily Ho; Jackilen Shannon
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-28

3.  Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.

Authors:  Peter M Wilson; Melissa J Labonte; Shelby C Martin; Stephanie T Kuwahara; Anthony El-Khoueiry; Heinz-Josef Lenz; Robert D Ladner
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

4.  Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression.

Authors:  Long Chen; Tingyi Wei; Xiaoxing Si; Qianqian Wang; Yan Li; Ye Leng; Anmei Deng; Jie Chen; Guiying Wang; Songcheng Zhu; Jiuhong Kang
Journal:  J Biol Chem       Date:  2013-03-29       Impact factor: 5.157

5.  A novel GRK2/HDAC6 interaction modulates cell spreading and motility.

Authors:  Vanesa Lafarga; Ivette Aymerich; Olga Tapia; Federico Mayor; Petronila Penela
Journal:  EMBO J       Date:  2011-12-23       Impact factor: 11.598

6.  Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.

Authors:  Tyler R McCaw; Mei Li; Dmytro Starenki; Mingyong Liu; Sara J Cooper; Rebecca C Arend; Andres Forero; Donald J Buchsbaum; Troy D Randall
Journal:  Cancer Immunol Immunother       Date:  2019-11-12       Impact factor: 6.968

7.  Epigenetic impact of long-term shiftwork: pilot evidence from circadian genes and whole-genome methylation analysis.

Authors:  Yong Zhu; Richard G Stevens; Aaron E Hoffman; Anne Tjonneland; Ulla B Vogel; Tongzhang Zheng; Johnni Hansen
Journal:  Chronobiol Int       Date:  2011-12       Impact factor: 2.877

8.  Effect of EGF-induced HDAC6 activation on corneal epithelial wound healing.

Authors:  Jie Wang; Andrew Lin; Luo Lu
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

9.  Histone acetylation regulates intracellular pH.

Authors:  Matthew A McBrian; Iman Saramipoor Behbahan; Roberto Ferrari; Trent Su; Ta-Wei Huang; Kunwu Li; Candice S Hong; Heather R Christofk; Maria Vogelauer; David B Seligson; Siavash K Kurdistani
Journal:  Mol Cell       Date:  2012-11-29       Impact factor: 17.970

10.  DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

Authors:  Melissa J LaBonte; Peter M Wilson; William Fazzone; Susan Groshen; Heinz-Josef Lenz; Robert D Ladner
Journal:  BMC Med Genomics       Date:  2009-11-30       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.